Bank of America Lowers Pfizer (NYSE:PFE) Price Target to $26.00

Pfizer (NYSE:PFE) had its target price decreased by analysts at Bank of America from $27.00 to $26.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Bank of America‘s price target suggests a potential upside of 7.19% from the company’s previous close.

Several other analysts have also recently issued reports on the stock. Guggenheim upped their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Wolfe Research reiterated an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Citigroup raised their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research report on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.56.

Pfizer Price Performance

Shares of PFE traded up $0.01 during mid-day trading on Friday, hitting $24.25. 14,144,687 shares of the company were exchanged, compared to its average volume of 42,506,410. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer has a 1-year low of $23.11 and a 1-year high of $28.75. The stock has a market cap of $138.24 billion, a price-to-earnings ratio of 18.51 and a beta of 0.35. The company has a 50 day moving average of $25.41 and a 200-day moving average of $26.20.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the business earned $0.92 earnings per share. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer will post 2.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Several large investors have recently made changes to their positions in PFE. Handelsbanken Fonder AB lifted its holdings in Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after purchasing an additional 232,528 shares during the last quarter. City Holding Co. raised its position in shares of Pfizer by 4.7% in the second quarter. City Holding Co. now owns 35,409 shares of the biopharmaceutical company’s stock valued at $852,000 after purchasing an additional 1,580 shares during the period. Charles Schwab Trust Co lifted its stake in shares of Pfizer by 66.1% during the 2nd quarter. Charles Schwab Trust Co now owns 16,129 shares of the biopharmaceutical company’s stock worth $388,000 after buying an additional 6,419 shares during the last quarter. Spinnaker Investment Group LLC grew its stake in Pfizer by 115.2% in the 2nd quarter. Spinnaker Investment Group LLC now owns 22,810 shares of the biopharmaceutical company’s stock valued at $549,000 after buying an additional 12,211 shares during the last quarter. Finally, KMG Fiduciary Partners LLC lifted its holdings in shares of Pfizer by 26.4% during the second quarter. KMG Fiduciary Partners LLC now owns 190,888 shares of the biopharmaceutical company’s stock worth $4,597,000 after buying an additional 39,875 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The biggest catalyst is the FDA approval of PADCEV plus Keytruda for muscle-invasive bladder cancer, a label expansion that could support Pfizer’s oncology revenue stream and strengthen the company’s long-term growth story. Article: U.S. FDA Approves PADCEV plus Keytruda as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
• Positive Sentiment: Pfizer also disclosed updates from ongoing clinical work, including its lorlatinib lung cancer study and a Phase 1 bioavailability study, which keep attention on its pipeline and suggest continued development activity across key programs. Article: Pfizer’s Lorlatinib Lung Cancer Study Wraps Up, Offering Fresh Signals for PFE Investors Article: Pfizer Refines Early-Stage Drug Formulations With New Phase 1 Bioavailability Study
• Positive Sentiment: Investors are also encouraged by commentary that Pfizer has a solid chance to beat earnings expectations again, which supports the idea that the stock may be undervalued if execution improves. Article: Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Several articles focused on Pfizer as a value and dividend stock, reinforcing its appeal to income investors, but these pieces do not appear to add a new near-term catalyst by themselves. Article: McDonald’s or Pfizer: One Offers Real Growth, One Just Pays You to Wait
• Negative Sentiment: Offsetting the upbeat pipeline news, Pfizer continues to face questions about growth momentum and the performance of the Seagen acquisition, while vaccine disputes with Poland and Romania remain unresolved and could keep legal and political pressure on the company. Article: Market Chatter: Pfizer’s Vaccine Disputes With Poland, Romania Continue Article: Jim Cramer on Pfizer: “I Can’t Come Up With Where the Growth Is”

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.